| Anti-fibrotic Potential of AT2 Receptor Agonists Y Wang, M Del Borgo, HW Lee, D Baraldi, B Hirmiz, TA Gaspari, ... Frontiers in Pharmacology 8, 564, 2017 | 64 | 2017 |
| AT1R-AT2R-RXFP1 functional crosstalk in myofibroblasts: impact on the therapeutic targeting of renal and cardiac fibrosis BSM Chow, M Kocan, M Shen, Y Wang, L Han, JY Chew, C Wang, ... Journal of the American Society of Nephrology 30 (11), 2191-2207, 2019 | 39 | 2019 |
| β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious … M Del Borgo, Y Wang, S Bosnyak, M Khan, P Walters, I Spizzo, ... Clinical Science 129 (6), 505-513, 2015 | 36 | 2015 |
| Serelaxin and the AT2 Receptor Agonist CGP42112 Evoked a Similar, Nonadditive, Cardiac Antifibrotic Effect in High Salt-Fed Mice That Were Refractory to … Y Wang, L Han, M Shen, ES Jones, I Spizzo, SL Walton, KM Denton, ... ACS Pharmacology & Translational Science 3 (1), 76-87, 2020 | 15 | 2020 |
| Preclinical rodent models of cardiac fibrosis Y Wang, M Wang, CS Samuel, RE Widdop British Journal of Pharmacology 179 (5), 882-899, 2022 | 14 | 2022 |
| A framework of biomarkers for vascular aging: a consensus statement by the Aging Biomarker Consortium Aging Biomarker Consortium, L Zhang, J Guo, Y Liu, S Sun, B Liu, Q Yang, ... Life Medicine 2 (4), lnad033, 2023 | 7 | 2023 |
| The novel AT2 receptor agonist β-Pro7-AngIII exerts cardiac and renal anti-fibrotic and anti-inflammatory effects in high salt-fed mice Y Wang, J Yodgee, M Del Borgo, I Spizzo, L Nguyen, MI Aguilar, ... International Journal of Molecular Sciences 23 (22), 14039, 2022 | 6 | 2022 |
| A biomarker framework for cardiac aging: the Aging Biomarker Consortium consensus statement Aging Biomarker Consortium, W Zhang, Y Che, X Tang, S Chen, M Song, ... Life Medicine 2 (5), lnad035, 2023 | 1 | 2023 |
| Functional crosstalk between angiotensin receptors (types 1 and 2) and relaxin family peptide receptor 1 (RXFP1): Implications for the therapeutic targeting of fibrosis CS Samuel, Y Li, Y Wang, RE Widdop British Journal of Pharmacology, 2022 | 1 | 2022 |
| AT1 R-AT2 R-RXFP1 functional crosstalk: implications for the therapeutic targeting of fibrosis. CS Samuel, Y Li, Y Wang, RE Widdop British Journal of Pharmacology, 2022 | | 2022 |
| Angiotensin receptor agonists and uses thereof R Widdop, MI Aguilar, M Del Borgo, E Jones, B Hirmiz, Y Wang US Patent 11,331,368, 2022 | | 2022 |
| [PP. 07.23] SERELAXIN ATTENTUATES THE PRESSOR RESPONSE TO ANGIOTENSIN II IN AGEING FEMALES VIA AN ANGIOTENSIN TYPE 2 RECEPTOR MEDIATED PATHWAY KM Colafella, L Hilliard, T Gaspari, Y Wang, R Widdop, C Samuel, ... Journal of Hypertension 35, e143, 2017 | | 2017 |
| PS 07-27 ANTI-FIBROTIC EFFECTS OF AT2 RECEPTOR AND MAS RECEPTOR STIMULATION IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS R Widdop, D Baraldi, Y Wang, E Jones, T Gaspari Journal of Hypertension 34, e290, 2016 | | 2016 |
Robert WiddopHead of Dept Pharmacology, Monash UniversityE-mail megerősítve itt: monash.edu
